Drug intelligence / Profile preview

AphoelineBrake

Development stage: Phase 2
Modality: Small Molecules
Administration: Oral

Overview

AphoelineBrake is a natural product investigated as an adjunct to standard treatment in patients with obesity and metabolic disease. Its primary research focus is on evaluating its effects on metabolic disease control, gastrointestinal hormones, inflammatory markers, diet, hunger, satiety, and weight compared to placebo. Secondary objectives include studying its impact on oxidative and inflammatory stress markers. The precise mechanism of action has not been specified in available sources; it is classified as a natural product rather than a conventional pharmaceutical agent[1].

Brand names: AphoelineBrake
Other names: AphoelineBrake

Beyond the preview

Go deeper on AphoelineBrake.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AphoelineBrake.

Explore the full profile